TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03231917

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Water Infusion first
Description: In this group patients will receive a colonoscopy with water infusion for mucosal inspection and then receive a colonoscopy with CO2 insufflation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CO2 Insufflation First
Description: In this group patients will receive a colonoscopy with CO2 insufflation for mucosal inspection and then receive a colonoscopy with water infusion .
Study: NCT00442533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indium-111 pentetreotide
Description: 4 cycles of 500 mCi treatments every 10-12 weeks
Study: NCT04214262

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study: NCT01764477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRI-724
Description: Gemcitabine: 1000 mg/m2 IV over 30 minutes; once weekly dosing; 3 weeks on with 1 week recovery (4 weeks per cycle)~PRI-724:~Cohort 1: 320 mg/m2/day; Cohort 2: 640 mg/m2/day; Cohort 3: 905 mg/m2/day; Continuous IV over 24 hours; daily x 7 days; 1 week on with 1 week recovery × 2 (4 weeks per cycle)
Study: NCT03935672

Intervention type: PROCEDURE
Group type: OTHER
Intervention: PET-CT scans
Description: Patients will have three scans during the trial.~* The 1st scan (prePET) is a baseline diagnostic scan. The patient is in a thermoplastic shell and PET CT will be used by to define a bGTV_P. bGTV_P will then be used as an adjunct to help us delineate the GTV_P.~* The 2nd scan (iPET) takes place following 2 weeks (10 fractions) of chemo-radiotherapy. The patient is in a thermoplastic shell and the PET CT will be used to delineate the remaining avid disease (bGTV_iP).~* The 3rd scan takes place 3 months following the last dose of radiotherapy. It will be used to ascertain whether any avid disease remains and may inform the need for further treatment.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Outlining the biological GTVs (bGTV_P and bGTV_iP)
Description: The biological GTVs (bGTV_P and bGTV_iP) will be automatically delineated by ATLAAS and verified manually by a nuclear medicine physician and a clinical oncologist. It will consist of the high FDG uptake volume based on visual assessment whilst using suitable windowing levels. Any differences in contouring will be settled either by the two doctors reaching a consensus or by a third doctor if differences between the first two cannot be resolved.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood samples for cell-free DNA analysis
Description: In order to contribute to our understanding of how disease processes may be monitored in a less invasive and less morbid manner, we will be collecting blood and saliva samples prior to, during, and after the radical treatment of OPSCC in PEARL, to see if there is correlation with disease status and FDG-PET-CT response.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Salivary samples for cell-free DNA analysis
Description: In order to contribute to our understanding of how disease processes may be monitored in a less invasive and less morbid manner, we will be collecting blood and saliva samples prior to, during, and after the radical treatment of OPSCC in PEARL, to see if there is correlation with disease status and FDG-PET-CT response.
Study: NCT04145544

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of the ArtiFascia®
Description: Following are the general instructions for use for the ArtiFascia®:~* Cut the ArtiFascia® to the required shape under aseptic conditions~* Apply ArtiFascia® to the damaged area~* Suture the ArtiFascia® in place~* Suture bites should be taken 2-3 millimeters from the edges of the implant. Either a running suture or interrupted stitches' technique may be used, depending on clinical conditions or surgeon's decision.~Important Note: If clinically possible, do not use dural adhesive or sealants as it is an uncontrolled variable, that can influence the results.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of other commercial suturable dural substitute
Description: Implantation of the commercial suturable dural substitute will be according to clinical discretion of the physician, and in compliance with each specific device instructions for use. Detailed instructions are in the instructions for use
Study: NCT00599534

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: 4 mg oral tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5mg tablets
Study: NCT04044053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571 400 mg Immediate Release (IR) in Fed State
Description: 400 mg IR dose in fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571 50 mg Modified Release (MR) in Fed State
Description: 50 mg MR in fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571 400 mg MR in Fed State
Description: 400 mg MR in fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571 400 mg MR in Fed State
Description: 400 mg MR in fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571 400 mg MR in Fasted State
Description: 400 mg MR in fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571 400 mg MR in Fasted State
Description: 400 mg MR in fasted state
Study: NCT01195376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235
Study: NCT00344318

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine GSK1024850A
Description: 3 Intramuscular injections.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine GSK1024850A
Description: 3 Intramuscular injections.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar
Description: 3 Intramuscular injections

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar
Description: 3 Intramuscular injections

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tritanrix-HepB
Description: 3 Intramuscular injections

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tritanrix-HepB
Description: 3 Intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix-HepB
Description: 3 Intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix-HepB
Description: 3 Intramuscular injections

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hiberix
Description: Reconstituted with Tritanrix before injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hiberix
Description: Reconstituted with Tritanrix before injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hiberix
Description: Reconstituted with Tritanrix before injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hiberix
Description: Reconstituted with Tritanrix before injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Polio Sabin.
Description: 3 oral doses.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Polio Sabin.
Description: 3 oral doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polio Sabin.
Description: 3 oral doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polio Sabin.
Description: 3 oral doses.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Poliorix.
Description: 3 intramuscular injections

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Poliorix.
Description: 3 intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Poliorix.
Description: 3 intramuscular injections
Study: NCT01035515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB014 50mg
Description: Single dose oral capsule 50mg BIIB014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB014 100mg
Description: Single dose oral capsule 100mg BIIB014
Study: NCT00344318

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Poliorix.
Description: 3 intramuscular injections
Study: NCT03228459

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dried blood spot test
Description: Dried capillary blood testing creatinine, uric acid and total cholesterol (reflotron® Plus system, Roche). Determination of the complete lipid profile in cases in which total cholesterol is greater than 200 mg/dl: HDL cholesterol (mg/dl), LDL cholesterol (mg/dl) and triglycerides (mg/dl) (Cobas B 101® system, Roche). Calculation of non-HDL cholesterol levels. Glycated haemoglobin will be analysed with the Cobas B 101 system,Roche. The CKD-EPI glomerular filtration rate will be determined.
Study: NCT01035515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB014 100mg
Description: Single dose oral capsule 100mg BIIB014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB014 100mg
Description: Single dose oral capsule 100mg BIIB014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB014 100mg
Description: Single dose oral capsule 100mg BIIB014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB014 100mg
Description: Single dose oral capsule 100mg BIIB014
Study: NCT03666468

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online Package
Description: Online package (OP) of NSW Health Guidelines focused on Paediatric Asthma and Seizure management
Study: NCT01035515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB014 100mg
Description: Single dose oral capsule 100mg BIIB014
Study: NCT03228459

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urine test
Description: A urine sample from spontaneous micturition will be collected and analyzed using Clinitek Microalbumin 2 Reagent Strips and a Siemens Clinitek Status® analyzer. It will be determined albuminuria (mg/l) and albumin/creatinine ratio (mg/g).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Artery ultrasound
Description: Carotid and femoral artery ultrasound for atheroma plaque diagnosis. Abdominal aorta ultrasound for early diagnosis of aortic aneurism. Transcranial ultrasound for cerebral arterial blood flow alterations.
Study: NCT00793598

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brincidofovir
Study: NCT03151837

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Greenyn Momordica charantia extracts
Description: Extracts from Momordica charantia containing Momordica charantia insulin receptor binding protein (mcIRBP)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Starch
Study: NCT00000383

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-Focused CBT
Description: Structured skills, exposure, trauma-specific interventions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Child-Centered Therapy
Description: Client-directed supportive interventions
Study: NCT03228459

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ankle-brachial index
Description: Systolic blood pressure measurement in the brachial artery, posterior tibial artery and dorsalis pedis artery in both limbs. The ratios between tibial and pedal systolic blood pressure in each leg and the higher brachial blood pressure will be calculated.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Spirometry
Description: Spirometry will be used to assess lung capacity. It will be performed by the same nurse who will measure forced vital capacity (FVC); forced expiratory volume in one second (FEV1); the ratio between FEV1 and FVC and the lower limit of normality, as a percentage.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Determination of advanced glycation-end products
Description: These will be measured using skin autofluorescence (SAF) in the forearm with the AGE Reader® system (Diagnostics, the Netherlands). SAF is measured using spectrophotometry which is calculated as the relationship of the intensity of reflected light compared to refracted light.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation screening
Description: The presence of atrial fibrillation is assessed with a device (SRA, EVINA Health Solutions) during one hour in the mobile unit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological sample collection
Description: Blood samples from a peripheral vein of the hand or forearm to obtain serum, plasma, DNA and RNA will be collected. Moreover, a saliva sample will be collected.These samples will be prepared in aliquots following a standardized protocol, and sent frozen (dry ice) to a centralized biobank (IRBLleida Biobank, Spain) for processing and storage for subsequent studies of CV, inflammatory and mineral-metabolism biomarkers and genetic polymorphisms. Urine samples will be frozen and stored in a biobank for subsequent study of biomarkers.
Study: NCT03666468

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Paper Guidelines
Description: Paper NSW Health Guideline focused on Paediatric Asthma and Seizure management
Study: NCT05769244

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: near-infrared spectroscopy (NIRS)
Description: NIRS measurements will be performed on each testicle on a group of healthy boys and on a group of boys under 18 years consulting to emergency for scrotal pain
Study: NCT02243332

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KneeStim mobile rehabilitation assistance device
Description: KneeStim is a neuromuscular electrical stimulation (NMES) device that integrates motion-tracking hardware like three-axis accelerometers and a real-time operating system to enable quadriceps muscle stimulation in time with user gait. It is a completely non-invasive device that looks like a light brace and fastens to the user's quadriceps and gastrocnemius muscles. The end goal of this device is to assist with muscle re-strengthening and re-education during a user's everyday activities.
Study: NCT03780283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: Participants receive Anlotinib 12mg, administered as PO on Day1-14 of each 21-day cycle until documented PD or had unacceptable toxicity
Study: NCT02671396

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality based intervention
Description: Virtual reality based balance training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional intervention
Description: Conventional balance training
Study: NCT03731611

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical Cord Milking
Description: Umbilical cord milking (UCM) is typically performed by placing the infant below the level of the placenta. The cord is held at 20-25 cm distance from the baby and milked vigorously towards the umbilicus for 3 times at a speed of 10 cm/sec. After completion, the cord is clamped, and the neonate is handed to the resuscitation team.
Study: NCT03228459

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Result and recommendation report
Description: A report with exploration results and recommendations based on the current guidelines will be uploaded to the e-CAP history for the Primary care evaluation.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pulse wave velocity
Description: Pulse wave velocity (PWV) will be used as an indicator of arterial stiffness. It will be measured non-invasively with the carotid to femoral PWV (cfPWV) according to standard protocols.
Study: NCT01755962

Intervention type: OTHER
Group type: OTHER
Intervention: Glycemic Load

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glycemic Load

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glycemic Load

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glycemic Load

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Study: NCT02340208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-DOS47
Description: A treatment cycle will be 21 days with patients receiving L-DOS47 on cycle Days 1 and 8.
Study: NCT03482648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBT-401-1S, Single dose
Description: Single dose of BBT-401-1S, 7 dose levels, oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBT-401-1S, Multiple doses
Description: Multiple doses of BBT-401-1S, 7 days, 3 dose levels, oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to BBT-401-1S, oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to BBT-401-1S, oral capsule
Study: NCT03896789

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEGASUS Program for Care
Description: This is in essence a checklist of pediatric guidelines to follow for participants who meet inclusion criteria. Site staff will receive training in how to implement this pathway into their usual care.
Study: NCT02921217

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active Probiotic
Description: Product 1: 200 mg maltodextrin and 100 mg of active Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145) (1011 CFU/g),

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inactivated probiotic
Description: Product 1: 200 mg maltodextrin and 100 mg of Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145) inactivated by heat (1011 CFU/g),
Study: NCT05769244

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: near-infrared spectroscopy (NIRS)
Description: NIRS measurements will be performed on each testicle on a group of healthy boys and on a group of boys under 18 years consulting to emergency for scrotal pain

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: near-infrared spectroscopy (NIRS)
Description: NIRS measurements will be performed on each testicle on a group of healthy boys and on a group of boys under 18 years consulting to emergency for scrotal pain
Study: NCT02921217

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Placebo: 300 mg maltodextrin.
Study: NCT02136641

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Was applied Midazolam 0.03 mg / kg, IV (in the vein), single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam+Fentanyl Combination
Description: Was applied Midazolam 0.015 mg / Kg + Fentanyl 0.8mcg/kg, IV (in the vein), single dose.
Study: NCT03008668

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: a stimulation of the body or auricular points

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: a stimulation of the body or auricular points
Study: NCT02136641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam+Ketamine Combination
Description: Was applied Midazolam 0,015 mg / Kg + ketamine 0.25 mg / kg, IV (in the vein), single dose.
Study: NCT02540824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib single agent arm
Description: For RET-fusion positive advanced NSCLC patients who failed to previous treatment,treat with apatinib, single agent, 750mg once daily, p.o until disease progression
Study: NCT01611493

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Osseotite Prevail Implant
Description: Osseotite Prevail will be placed in sites with native bone, with at least three months of healing since tooth extraction or four months from bone augmentation grafting procedure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Osseotite Non Prevail Implant
Description: Osseotite Non Prevail Implant will be placed in sites with native bone, with at least three months of healing since tooth extraction or four months from bone augmentation grafting procedure
Study: NCT00982644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
Study: NCT02023346

Intervention type: BEHAVIORAL
Intervention: surveys and cognitive tests
Study: NCT02695134

Intervention type: OTHER
Group type: OTHER
Intervention: Healing Touch
Description: Healing Touch (HT) is an energy based approach to health and healing. It uses light touch to influence the energy field that surrounds the body, and energy centers which control the flow of energy to the physical body.
Study: NCT04492475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Description: Rebif (R) is a purified 166 amino acid human interferon beta glycoprotein with an amino acid sequence identical to natural fibroblast derived human interferon beta. Each 0.5 mL prefilled syringe contains 44 mcg of interferon beta-1a, 4 mg human albumin, USP; 27.3 mg mannitol, USP; 0.4 mg sodium acetate; and water for injection, USP.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The interferon beta-1a placebo contains either 0.5 mL 0.9% normal saline or 0.5 mL sterile water for injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Drug Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of Remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remdesivir
Description: Drug Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of Remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.
Study: NCT05462067

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AT LARA IOL
Description: EDOF IOL for treatment of cataract

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AT LARA IOL
Description: EDOF IOL for treatment of cataract

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AT LISA Tri IOL
Description: Trifocal IOL for treatment of cataract
Study: NCT01756924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEM-102

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV or Oral standard of care antibiotics

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin